-
$21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
-
Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
-
Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability
Breakthrough Solutions for Human Primary Cells & Hematologic Tissue Products
AllCells is a biotechnology company that specializes in biologically relevant, high quality primary cells to enable drug discovery, development, and manufacturing of cell therapies. Leveraging its expertise in hematological and immune cell isolations, combined with on-site whole blood and bone marrow tissue collection operations, AllCells maintains one of the world’s largest and most diverse repositories of donor profiles that can be screened and qualified for biomedical applications.
I had the honor of interviewing Dr. Jay Tong, President and CEO of AllCells. In this interview, we discuss AllCells history, its leadership in blood donor cell collections and hematologic tissue products and the recent opening of its newest facility in Boston, Massachusetts. We also explore the company’s long-term goals and expansion into the cell therapy development space. [Read more…]
Invenra, Inc. Appoints Daniel S. Pereira, Ph.D., as Chief Scientific Officer
Invenra builds out management team to advance immuno-oncology therapeutics pipeline and collaborative discovery efforts
MADISON, Wis., Jan 5, 2022 — Invenra, Inc., a biotechnology company focused on the discovery and development of multispecific antibodies for immuno-oncology, today announced the appointment of Daniel S. Pereira, Ph.D., as Chief Scientific Officer. Dr. Pereira brings more than 20 years of experience in oncology biologics drug discovery and development in biotech and pharma as a scientific leader, strategist, innovator, collaborator and fundraiser. His career efforts have led to the discovery and development of a range of FDA-approved drugs for patients with cancer. [Read more…]
What is Cord Tissue Banking?
Cord tissue banking is the processing and storage of a newborn’s umbilical cord tissue or the components contains, such as Wharton’s jelly. Wharton’s jelly is a thick, gelatinous substance present within the human umbilical cord that contains a range of important cell types, such as mesenchymal stem cells (MSCs), fibroblasts and macrophages.
In this article:
BlueCube Bio Becomes Evia Bio™ and Launches iPSC Cryopreservation Solution for Cell & Gene Therapies
MINNEAPOLIS, Dec. 9, 2021 — BlueCube Bio officially announced a company name transition to Evia Bio™, concurrent with the launch of a significant new cryopreservation technology for use in cell and gene therapies utilizing Induced Pluripotent Stem Cells (iPSCs). The osmolyte-based solution increases cell survival above that of commercially available DMSO-based options which is critical for realizing the potential of these therapies. This latest addition expands the company’s portfolio of patented cryopreservation products that also include products for mesenchymal stem cells (MSCs). [Read more…]
- « Previous Page
- 1
- …
- 153
- 154
- 155
- 156
- 157
- …
- 336
- Next Page »